Next Article in Journal
Maternal Blood Concentration of Tadalafil and Uterine Blood Flow in Pregnancy
Previous Article in Journal
The Relationship between the Soluble Receptor for Advanced Glycation End Products and Oxidative Stress in Patients with Palmoplantar Warts
Previous Article in Special Issue
Emerging Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
Open AccessReview

Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib

1
Medical Oncology Unit, National Cancer Research Centre, IRCCS Istituto Tumori “Giovanni Paolo II”, 70124 Bari, Italy
2
Medical Oncology Unit, “S. Cuore di Gesù” Hospital, 73014 Gallipoli, Italy
3
Medical Thoracic Oncology Unit, IRCCS Istituto Tumori “Giovanni Paolo II”, 70124 Bari, Italy
4
Radiology Unit, National Cancer Research Centre, IRCCS Istituto Tumori “Giovanni Paolo II”, 70124 Bari, Italy
5
Scientific Direction, National Cancer Research Centre, IRCCS Istituto Tumori “Giovanni Paolo II”, 70124 Bari, Italy
6
Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine “G. Baccelli”, University of Bari Medical School, 70124 Bari, Italy
7
Department of Medical Oncology, IstitutoScientifico Romagnolo per Lo Studio e Cura Dei Tumori (IRST) IRCCS, 47014 Meldola, Italy
8
Department of Oncology and Haematology, University Hospital of Modena, 41125 Modena, Italy
9
Department of Biomedical Sciences and Human Oncology, University of Bari “Aldo Moro”, 70124 Bari, Italy
*
Author to whom correspondence should be addressed.
Medicina 2019, 55(10), 707; https://doi.org/10.3390/medicina55100707
Received: 5 September 2019 / Revised: 16 October 2019 / Accepted: 16 October 2019 / Published: 21 October 2019
(This article belongs to the Special Issue Liver Cancer: Molecular Mechanisms and Targeted Therapies)
Sorafenib is an oral kinase inhibitor that enhances survival in patients affected by advanced hepatocellular carcinoma (HCC). According to the results of two registrative trials, this drug represents a gold quality standard in the first line treatment of advanced HCC. Recently, lenvatinib showed similar results in terms of survival in a non-inferiority randomized trial study considering the same subset of patients. Unlike other targeted therapies, predictive and prognostic markers in HCC patients treated with sorafenib are lacking. Their identification could help clinicians in the daily management of these patients, mostly in light of the new therapeutic options available in the first. View Full-Text
Keywords: Sorafenib; hepatocellular carcinoma; prognostic factors; predictive factors Sorafenib; hepatocellular carcinoma; prognostic factors; predictive factors
Show Figures

Figure 1

MDPI and ACS Style

Brunetti, O.; Gnoni, A.; Licchetta, A.; Longo, V.; Calabrese, A.; Argentiero, A.; Delcuratolo, S.; Solimando, A.G.; Casadei-Gardini, A.; Silvestris, N. Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib. Medicina 2019, 55, 707.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop